18Fluorodeoxyglucose positron emission tomography, a standard diagnostic tool in lung cancer

Journal of the National Cancer Institute

Volumn 99, Issue 23, 2007, Pages 1741-1743

  Giaccone, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; EDITORIAL; HUMAN; INTERMETHOD COMPARISON; LUNG NODULE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; BIOMEDICAL TECHNOLOGY ASSESSMENT; DIFFERENTIAL DIAGNOSIS; LUNG COIN LESION; LUNG TUMOR; LYMPH NODE METASTASIS; MEDIASTINUM TUMOR; METASTASIS; NOTE; PATHOLOGY; SCINTISCANNING;

CARCINOMA, NON-SMALL-CELL LUNG; COIN LESION, PULMONARY; DIAGNOSIS, DIFFERENTIAL; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MEDIASTINAL NEOPLASMS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 38449092009     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djm245     Document Type: Editorial

References (12)

1. 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. J Natl Cancer Inst 2007;99:1753-67.
2. O JH Yoo Ie R, Kim SH, Sohn HS, Chung SK. Clinical significance of small pulmonary nodules with little or no 18F-FDG uptake on PET/CT images of patients with nonthoracic malignancies. J Nucl Med 2007;48:15-21.
3. Veronesi G, Bellomi M, Veronesi U, Paganelli G, Maisonneuve P, Scanagatta P, et al. Role of positron emission tomography scanning in the management of lung nodules detected at baseline computed tomography screening. Ann Thorac Surg 2007;84:959-65; discussion 965-6.
4. van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359:1388-93.
5. Viney RC, Boyer MJ, King MT, Kenny PM, Pollicino CA, McLean JM, et al. Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol 2004;22:2357-62.
6. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-53.
7. Freudenberg LS, Rosenbaum SJ, Beyer T, Bockisch A, Antoch G. PET versus PET/CT dual-modality imaging in evaluation of lung cancer. Radiol Clin North Am 2007;45:639-44, v.
8. Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000;343:254-61.
9. Tournoy KG, Maddens S, Gosselin R, Van Maele G, van Meerbeeck JP, Kelles A. Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study. Thorax 2007;62:696-701.
10. Detterbeck FC, Jantz MA, Wallace M, Vansteenkiste J, Silvestri GA. Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132 Suppl:202S-20S.
11. Niho S, Fujii H, Murakami K, Nagase S, Yoh K, Goto K, et al. Detection of unsuspected distant metastases and/or regional nodes by FDG-PET in LD-SCLC scan in apparent limited-disease small-cell lung cancer. Lung Cancer 2007;57:328-33.
12. Ohno Y, Koyama H, Nogami M, Takenaka D, Yoshikawa T, Yoshimura M, et al. Whole-body MR imaging vs. FDG-PET: comparison of accuracy of M-stage diagnosis for lung cancer patients. J Magn Reson Imaging 2007;26:498-509.